UNSPSC 51172907: Lactic acid/methyl salicylate/octoxynol 9/sodium bicarbonate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU900. This VA Drug Class (GU900) classifies this compound as belonging to the group GENITO-URINARY AGENTS, OTHER.

UNSPSC 51172907 Lactic acid/methyl salicylate/octoxynol 9/sodium bicarbonate is a Commodity code under which state and local governments procure chemical and pharmaceutical products for water treatment, healthcare, and facility operations. Recent solicitations under this code show divergent scope: the City of Meriden sought sodium bisulfite specifically for a municipal water pollution control facility, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) solicited generic multi-source pharmaceuticals and over-the-counter products for distribution across state and local government facilities including Oregon. The issuing bodies range from individual cities managing water infrastructure to state-administered cooperative purchasing alliances serving multiple jurisdictions. Pharmaceutical and OTC products dominate the recent activity, with state and local agencies using established wholesaler networks (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson Co.) to standardize procurement and pricing across member organizations.

The code shows recent activity in Connecticut and Minnesota, with the MMCAP solicitation extending to Oregon and other participating states in the multistate cooperative. The City of Meriden issued an IFB (solicitation B027-15) for sodium bisulfite with a due date of July 29, 2026, requiring General Liability coverage of $1,000,000 to $2,000,000 and performance and labor-material payment bonds. MMCAP issued an RFP (S1070000015802) due March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products effective July 1, 2026, with vendors required to maintain commercial general liability of $5,000,000 per occurrence and comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act. MMCAP's evaluation weights price competitiveness at 75 percent, with fixed pricing, administrative compliance, EDI capability, and willingness to accept a 3 percent administrative fee comprising the remaining 25 percent.